Monday, May 6, 2013
Some of the 16 diseases FDA
picked for its first round of public meetings under its Patient-Focused Drug
Development initiative are obvious choices where it is not hard to imagine why
the agency would need patient feedback. Others are genuine head-scratchers, and
at least one surprised its own patient advocates with its inclusion.
FDA declined to discuss its
rationale for the specific diseases it chose for the first round of meetings, which
will be held over fiscal 2013-15. A second round of four disease-focused
meetings is planned for FY16-FY17, bringing the total to 20, and the agency has
said it has additional ways of addressing patient concerns in diseases not
picked for the meetings.